Prevention of Parkinson's disease-related sudden death

Scorza, Fúlvio A.; Almeida, Antônio-Carlos G. de; Scorza, Carla A.; Finsterer, Josef

doi:10.6061/clinics/2021/e3266

Cited by 3 publications

(3 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although PD presents in a minor percentage of younger adults, the majority of patients (over 75%) are over the age of 65 ( Pringsheim et al, 2014 ; Deuschl et al, 2020 ). PD is a neurodegenerative disease attributed to progressive neuronal loss in the substantia nigra pars compacta, with typical clinical features including tremor, rigidity, bradykinesia/akinesia, and postural instability ( Scorza et al, 2021 ). Moreover, PD, inflicting a considerable societal and economic burden worldwide, serves as a principal cause of disability and mortality among the elderly ( Heemels, 2016 ; Berson et al, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

Causal relationship between circulating insulin-like growth factor-1 and Parkinson’s disease: a two-sample Mendelian randomization study

Xu,

Fan,

Yang

et al. 2024

Front. Aging Neurosci.

View full text Add to dashboard Cite

BackgroundLinear associations between circulating insulin-like growth factor-1 (IGF-1) levels and Parkinson’s disease (PD) have been evidenced in observational studies. Yet, the causal relationship between IGF-1 levels and PD remains obscure. We conducted Mendelian randomization to examine the correlation between genetically predicted IGF-1 levels and PD.MethodsBy reviewing genome-wide association studies (GWAS) that are publicly accessible, we uncovered SNPs linked to both serum concentrations of IGF-1 and PD. A two-sample Mendelian randomization (MR) analysis was carried out to evaluate the individual effect of IGF-1 on PD.ResultsIn a primary causal effects model in MR analysis, employing the inverse-variance weighted (IVW) method, IGF-1 levels exhibited a notable association with the risk of PD (OR, 1.020, 95% CI, 1.003–1.038, p = 0.0215). Multiple evaluations revealed that horizontal pleiotropy was improbable to distort the main results (MR-Egger: P PD intercept =0.719), and no bias was detected by leave-one-out analysis.ConclusionThis study unearthed evidence indicating that heightened IGF-1 levels might be causally correlated with an increased risk of PD.

show abstract

Section: Introductionmentioning

confidence: 99%

Causal relationship between circulating insulin-like growth factor-1 and Parkinson’s disease: a two-sample Mendelian randomization study

Xu,

Fan,

Yang

et al. 2024

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…Before 50 years of age, PD is rare [3], but a 5-10 fold increase in the incidences are observed from the sixth to the ninth decade of life [4]. Overall, the estimated 0.3% global prevalence was seen to rise rapidly to more than 3% in people over the age of 80 [5].…”

Section: Introductionmentioning

confidence: 99%

Unravelling the role of nutraceutical supplements in treatment of Parkinson’s Disease

Kakoty,

Kumar,

Parasar

et al. 2024

BIO Web Conf.

View full text Add to dashboard Cite

Parkinson’s Disease (PD) causes motor dysfunction that usually begins in the elderly population. The prevalence rate of PD is increasing significantly. Currently available therapies are able to manage the disease, however, they have certain side effects associated with long term usage. Hence, there is a dire need to bring therapies that can offer good treatment to PD with less side effects. Recent research has revealed that food supplements which are specifically rich in antioxidants and vitamins have shown better efficacy against PD with a better safety profile. Hence, the present study focuses on the role of nutraceuticals in treatment of PD. Nutritional supplements targeting PD pathology were explored between 2016 and 2022 through Scopus, google scholar and PubMed. The review deciphered the neuroprotective benefits of vitamins, minerals, natural compounds, and phytochemicals that might procrastinate or help in the prevention of PD’s progression by targeting some of the major pathological mechanisms such as oxidative stress, neuroinflammation, misfolding of alpha-synuclein, and mitochondrial dysfunction. Various studies indicating the potential of nutraceutical supplements are discussed in detail.

show abstract

“… 8 , 9 Despite the tremendous clinical and epidemiological relevance of these studies, Sudden Death in PD (SUDPAR), a rare but fatal event, contributes to the increased mortality in PD patients. 2 , 10 …”

mentioning

confidence: 99%

The implication of cardio-oncology on Parkinson's disease: answers begin to emerge

Almeida

Finsterer

Hajjar

2022

Clinics

Self Cite

View full text Add to dashboard Cite

Prevention of Parkinson's disease-related sudden death

Abstract: The effect of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea and uncontrolled hypertension -Study design and challenges during the COVID-19 pandemic. Clinics (Sao Paulo).

Cited by 3 publications

References 52 publications

Causal relationship between circulating insulin-like growth factor-1 and Parkinson’s disease: a two-sample Mendelian randomization study

Causal relationship between circulating insulin-like growth factor-1 and Parkinson’s disease: a two-sample Mendelian randomization study

Unravelling the role of nutraceutical supplements in treatment of Parkinson’s Disease

The implication of cardio-oncology on Parkinson's disease: answers begin to emerge

Contact Info

Product

Resources

About